Neoadjuvant Chemotherapy With Anthracycline-Based Regimen for BRCAness Tumors in Triple-Negative Breast Cancer

Published:February 07, 2020DOI:



      A subgroup of triple-negative breast cancer (TNBC) shows impaired BRCA1 function owing to causes other than mutation, which is called “BRCAness.” DNA-damaging agents are known to have more efficacy in BRCA1-mutant tumors than mitotic poisons. We conducted a prospective single-arm clinical trial of neoadjuvant chemotherapy (NAC) using an anthracycline-based regimen without taxanes for BRCAness TNBCs.

      Materials and methods

      BRCAness was examined using the multiplex ligation-dependent probe amplification (MLPA) method in TNBC cases. For BRCAness cases, NAC was performed with anthracycline-based regimens without additional taxanes.


      A total of 30 patients with TNBC were enrolled. MLPA was successfully performed in 25 patients. Eighteen patients (72%) showed BRCAness. Twenty-three patients received NAC as per the protocol. On analysis, the clinical response rate (complete response plus partial response) was 76.4%, and the pathological complete response rate was 35.3%.


      The interim analysis revealed that the pathological complete response rate was lower than estimated. Therefore, BRCAness by MLPA was not sufficient to predict the therapeutic response to anthracycline-based regimens in TNBC.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Surgical Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • James C.R.
        • Quinn J.E.
        • Mullan P.B.
        • Johnston P.G.
        • Harkin D.P.
        BRCA1, a potential predictive biomarker in the treatment of breast cancer.
        Oncologist. 2007; 12: 142-150
        • Scully R.
        • Ganesan S.
        • Vlasakova K.
        • Chen J.
        • Socolovsky M.
        • Livingston D.M.
        Genetic analysis of BRCA1 function in a defined tumor cell line.
        Mol Cell. 1999; 4: 1093-1099
        • Tassone P.
        • Tagliaferri P.
        • Perricelli A.
        • et al.
        BRCA1 expression modulates chemosensitivity of BRCA1-defective Hcc1937 human breast cancer cells.
        Br J Cancer. 2003; 88: 1285-1291
        • Sung M.
        • Giannakakou P.
        BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.
        Oncogene. 2014; 33: 1418-1428
        • Chabalier C.
        • Lamare C.
        • Racca C.
        • Privat M.
        • Valette A.
        • Larminat F.
        BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance.
        Cell Cycle. 2006; 5: 1001-1007
        • Byrski T.
        • Gronwald J.
        • Huzarski T.
        • et al.
        Hereditary breast cancer consortium. Response to Neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.
        Breast Cancer Res Treat. 2008; 108: 289-296
        • Kriege M.
        • Jager A.
        • Hooning M.J.
        • et al.
        The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
        Cancer. 2012; 118: 899-907
        • Wysocki P.J.
        • Korski K.
        • Lamperska K.
        • Zaluski J.
        • Mackiewicz A.
        Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of Brca1 mutations.
        Med Sci Monit. 2008; 14: SC7-SC10
        • Joosse S.A.
        • van Beers E.H.
        • Tielen I.H.
        • et al.
        Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
        Breast Cancer Res Treat. 2009; 116: 479-489
        • Lips E.H.
        • Mulder L.
        • Oonk A.
        • et al.
        Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.
        Br J Cancer. 2013; 108: 2172-2177
        • Lips E.H.
        • Laddach N.
        • Savola S.P.
        • et al.
        Quantitative copy number analysis by multiplex ligation-dependent probe amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.
        Breast Cancer Res. 2011; 13: R107
        • Vollebergh M.A.
        • Lips E.H.
        • Nederlof P.M.
        • et al.
        An ACGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
        Ann Oncol. 2011; 22: 1561-1570
        • Narui K.
        • Ishikawa T.
        • Shimizu D.
        • et al.
        Anthracycline could be essential for triple-negative breast cancer: a randomised phase ii study by the Kanagawa breast oncology group (Kbog) 1101.
        Breast. 2019; 47: 1-9
        • Ishikawa T.
        • Narui K.
        • Tanabe M.
        • et al.
        BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.
        Eur J Surg Oncol. 2016; 42: 999-1001
        • Kuroi K.
        • Toi M.
        • Tsuda H.
        • Kurosumi M.
        • Akiyama F.
        Issues in the assessment of the pathologic effect of primary systemic Therapy for breast cancer.
        Breast Cancer. 2006; 13: 38-48
        • Telli M.L.
        • Timms K.M.
        • Reid J.
        • et al.
        Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer.
        Clin Cancer Res. 2016; 22: 3764-3773
        • Timms K.M.
        • Abkevich V.
        • Hughes E.
        • et al.
        Association of brca1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
        Breast Cancer Res. 2014; 16: 475
        • Telli M.L.
        • Hellyer J.
        • Audeh W.
        • et al.
        Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
        Breast Cancer Res Treat. 2018; 168: 625-630
        • Tutt A.
        • Tovey H.
        • Cheang M.C.U.
        • et al.
        Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the Tnt trial.
        Nat Med. 2018; 05: 628-637
        • Turner N.
        • Tutt A.
        • Ashworth A.
        Hallmarks of 'BRCAness' in sporadic cancers.
        Nat Rev Cancer. 2004; 4: 814-819
        • Vollebergh M.A.
        • Lips E.H.
        • Nederlof P.M.
        • et al.
        Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
        Breast Cancer Res. 2014; 16: R47
        • Byrski T.
        • Huzarski T.
        • Dent R.
        • et al.
        Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.
        Breast Cancer Res Treat. 2014; 147: 401-405